tbuckley/cabot-search huggingface dataset:
THU0436 Usefulness of salivary glands ultrasonography in the non invasive early detection of subclinical glandular involvement in PSS
Authors: N. Luciano, C. Baldini, R. Pascale, A. Paolicchi, F. Ferro, D. Caramella, S. Bombardieri
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To evaluate ultrasonographic (US) changes in major salivary glands associated with primary Sjogren’s syndrome (pSS) and to determine the usefulness of US in pSS assessment at the diagnosis and during the follow-up. <h3>Methods</h3> Sonographic images of 46 consecutive cases of patients with a diagnosis of pSS (AECG criteria) were analyzed by the same radiologist recording the following US parameters: size, parenchymal echogenicity and fibrosis of all major salivary glands. The US findings were correlated to pSS patients’ demographic, clinical, histological and serological data. The ESSDAI was employed to assess pSS activity. Visual analogique scales (VAS) were used as measurement instruments for patients’ subjective symptoms (dry eye, dry mouth and fatigue). <h3>Results</h3> Forty-six pSS patients (19 newly diagnosed with a disease duration ≤1 yrs and 27 with a disease duration ≥2 yrs) were enrolled in the study. US features of major salivary glands chronic inflammation were found in 31/46 pSS patients (11/19 vs 20/27, p-value=ns). Eight out of 31 had a symptomatic salivary gland enlargement while 23/31 a subclinical asymptomatic involvement. US features of advanced pSS including inhomogeneous salivary glands with scattered small, oval, hypoechoic or anechoic areas were found in 6/46 pSS patients (1/19 vs 5/27; p-value ns). We found a statistically significant correlation between parotid involvement and disease duration (p=0.01). In particular, the size of the parotid glands was smaller in patients with established pSS with respect to newly diagnosed patients (4/19 vs 15/27, p-value=0.027). No differences were detected between the two groups of patients as far as submandibular glands size, hypoechoic, and inhomogeneous US signs and/or enlarged intra-glandular lymphonodes was related. The involvement of submandibular glands was correlated to the ESSDAI and to the presence of hypergammaglobulinemia, leucopenia and lymphocytopenia. US signs of chronic inflammation of both parotid and submandibular glands were more frequent in patients with a positivity for antinuclear antibodies, anti Ro-SSA and Rheumatoid Factor. <h3>Conclusions</h3> Major salivary glands US may be an useful tool in the early detection of subclinical glandular involvement in pSS with the advantage of noninvasiveness and ease of use. <h3>Disclosure of Interest</h3> None Declared
Abstract 1224: PDGFR as a novel target for the treatment of malignant peripheral nerve sheath tumors
Authors: Parag Patwardhan, William Tap, Elisa de Stanchina, Gary K. Schwartz
Journal: Cancer Research (2012)

Abstract Malignant peripheral nerve sheath tumor (MPNST) is a rare and highly aggressive tumor type that accounts for approximately 5-10% of soft tissue sarcomas. MPNSTs arise either spontaneously or in patients with type 1 neurofibromatosis (NF1). These tumors are highly resistant to chemotherapy and there are no effective treatment options. It has been demonstrated that MPNSTs with NF1 mutations are highly sensitive to the mTOR inhibitor rapamycin. However, inhibition of this pathway by rapamycin in sarcomas has been shown to release negative feedback inhibition of IGF-1R and activate AKT (pAKT). We have shown that treatment of MPNST cell lines (MPNST and ST8814) with rapamycin activates AKT, but not through IGF-1R, since IGF-1R is not expressed in these cells. This would suggest an alternate route for rapamycin induced AKT activation. To understand this process, we treated MPNST and ST8814 cells, with or without rapamycin, and used cellular lysates to determine whether the release of negative feedback by mTOR inhibition was mediated by alternate receptor tyrosine kinases (RTKs). Using RTK array profiling (R&amp;D Systems), our results indicate that both p-PDGFRα and p-PDGFRß are activated in response to rapamycin. Using imatinib (STI571) to target both PDGFRα and PDGFRß, we show that imatinib blocks rapamycin induced reactivation of pAKT. In order to rule out off target effects of imatinib, knockdown of PDGFR using siRNA followed by treatment with rapamycin recapitulates the effects observed with imatinib treatment. The combination of imatinib and rapamycin in MPNST cells resulted in a significant decrease in cell proliferation when compared to either of the two drugs alone. Mouse xenograft studies also show that tumor growth volume is decreased significantly when xenografts are treated with imatinib in combination with rapamycin compared to either drug alone. Taken together, our data strongly suggests that in MPNST cells, PDGFR pathway is involved in rapamycin mediated release of the negative feedback loop that activates pAKT. Furthermore, the targeting of PDGFR in combination with inhibitors of mTOR could provide a new therapeutic approach for the treatment of this disease. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1224. doi:1538-7445.AM2012-1224
MPs call for urgent cash injection to prevent collapse of NHS
Authors: A. O'Dowd
Journal: BMJ (2014)

Three high profile MPs associated with health issues have called for a major injection of funds into the NHS to prevent services from collapsing.

The former Conservative health secretary and former chairman of the House of Commons Health Committee, Stephen Dorrell, has called on the government to make a real terms increase in funding for the NHS over the next five years to allow the health service to function properly. …
Treatment of Complications of Respiratory Illnesses in Pediatric Practice
Authors: Edward H. Townsend, John F. Radebaugh
Journal: New England Journal of Medicine (1962)

IN a study of the role of antimicrobial agents in preventing complications during an epidemic of influenza Townsend1 defined a complication as a new sign or symptom of the respiratory tract and implied that such an occurrence might justify the use of antimicrobial agents in the patient's treatment program.By this definition, complications were reported as having developed in 12 per cent of the study group. On the other hand, some of the new signs and symptoms such as otitis media and bronchopneumonia defined as "complications" were found to be elements of the original illness. Therefore, in a subsequent study, . . .
TCT-864 A comparison Of The Femoral And Radial Crossover Techniques For Vascular Access Management In Transcatheter Aortic Valve Implantation: The Milan Experience
Authors: Helen Curran, Alaide Chieffo, Gill Louise Buchanan, Chiara Bernelli, Matteo Montorfano, Francesco Maisano, Azeem Latib, Filippo Figini, Micaela Cioni, Ottavio Alfieri, Antonio Colombo
Journal: Journal of the American College of Cardiology (2012)
Stat BiteTrends in Americans' Dietary Fat Intake
Authors: M. McDowell
Journal: JNCI Journal of the National Cancer Institute (1994)

Stat Bite Trends in Americans' Dietary Fat Intake Get access Margaret McDowell Margaret McDowell Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 12, 15 June 1994, Page 889, https://doi.org/10.1093/jnci/86.12.889 Published: 15 June 1994
611 PERSISTENCE OF COGNITIVE IMPAIRMENT AFTER OVERT HEPATIC ENCEPHALOPATHY: AN INTERNATIONAL, MULTI-CENTER PROSPECTIVE STUDY
Authors: J.S. Bajaj, R. Prakash, C. Pasquale, S. Allampati, S. Nardelli, F. Moscucci, N.A. Noble, M.B. White, S. Montagnese, P. Amodio, K.D. Mullen, O. Riggio
Journal: Journal of Hepatology (2012)
DISECCIÓN SUBMUCOSA Y RESECCIÓN TRANSMURAL DE LESIONES GÁSTRICAS ASISTIDAS CON IMANES
Authors: M Abu-suboh Abadia, J Dot Bach, J Armengol Bertrolí, A Benages Curell, M Masachs Peracaula, JC Salord Oses, SV Kantsevoy, H De Leon, M Moris, JR Armengol-Miró
Journal: Endoscopy (2011)

Introducción: En la cirugía NOTES y en la endoscopia intervencionista la posibilidad de utilizar un sistema para la fijación, la tracción o movilización de la lesión sin utilizar el canal de trabajo es una ventaja que podría hacer el procedimiento más fácil y seguro.
Association of Multiple Copies of the N-<i>myc</i>Oncogene with Rapid Progression of Neuroblastomas
Authors: Robert C. Seeger, Garrett M. Brodeur, Harland Sather, Andree Dalton, Stuart E. Siegel, Kwan Y. Wong, Denman Hammond
Journal: New England Journal of Medicine (1985)

Eighty-nine patients with untreated primary neuroblastomas were studied to determine the relation between the number of copies of the N-myc oncogene and survival without disease progression. Genomic amplification (3 to 300 copies) of N-myc was detected in 2 of 16 tumors in Stage II, 13 of 20 in Stage III, and 19 of 40 in Stage IV; in contrast, 8 Stage I and 5 Stage IV-S tumors all had 1 copy of the gene (P<0.01). Analysis of progression-free survival in all patients revealed that amplification of N-myc was associated with the worst prognosis (P<0.0001); the estimated progression-free survival at 18 months was 70 per cent, 30 per cent, and 5 per cent for patients whose tumors had 1, 3 to 10, or more than 10 N-myc copies, respectively. Of 16 Stage II tumors, 2 with amplification metastasized, whereas only 1 of 14 without amplification did so (P = 0.03). Stage IV tumors with amplification progressed most rapidly: nine months after diagnosis the estimated progression-free survival was 61 per cent, 47 per cent, and 0 per cent in patients whose tumors had 1, 3 to 10, or more than 10 copies, respectively (P<0.0001). These results suggest that genomic amplification of N-myc may have a key role in determining the aggressiveness of neuroblastomas. (N Engl J Med 1985; 313: 1111–6.)
Abstract 5097: ITCH E3 ubiquitin ligase regulates LATS1 tumor suppressor stability
Authors: King Ching Ho, Xiaolong Yang
Journal: Cancer Research (2010)

Abstract The Large Tumour Suppressor 1 (LATS1) is a serine/threonine kinase and tumour suppressor found downregulated in many human tumour types. Our lab and others previously revealed that LATS1 plays critical regulatory roles in various cancer development events, including cell proliferation, cell migration and apoptosis. However, despite such biological importance, relatively little is known regarding to how LATS1 is regulated at the molecular level. Through a recent binidng screen, we identified a HECT class E3 ubiqitin ligase ITCH (or API4) as a novel binding partner of LATS1. Further mapping showed that this interaction is particularly mediated through the PPxY (P, proline; x, any amino acids; Y, tyrosine) motifs of LATS1 and the WW domains of ITCH. Significantly, we found that ectopic expression of ITCH readily promotes downregulation of LATS1 proteins in a dose dependent manner and that this effect requries an intact ligase activity of ITCH. Further experiments also revealed that ITCH can promote in vivo polyubiquitination and subsequent degradation of LATS1 through the 26S proteasome pathway. Consistent with these results, stable shRNA knockdown of endogenous ITCH also causes upregulation of endogenous LATS1 in the MDA-MB-231 breast cancer cells, suggesting ITCH is a direct regulator of LATS1's protein stability. Together, our study provided convincing evidences demonstrating ITCH as the first negative regulator of the LATS1 tumour suppressor. Further elucidation of the effect of ITCH on LATS1's tumour suppressive activity may therefore shed light on our understanding of their roles in cancer development and therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5097.
SP0102 Raising Awareness - the Perspective of Pare
Authors: M. Kouloumas
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> In the area of Rheumatic and Musculoskeletal diseases there are many myths and misperceptions, we are all witness to “it is a disease of the elderly”, “we can9t do much”, “it is just pain” etc. These misconceptions are not only occurring among the general public, but also among the policy makers, the scientific society and in many cases among the people with RMDs as well. There is a need to bring these issues to the surface and to inform and educate all the stakeholders for the realistic facts of RMDs, the benefits if we effectively tackle these diseases, to share the patient perspective and a call to act immediately in order to improve the life of more than 120,000,000 people with RMDs in Europe. The Standing Committee of PARE (people with arthritis and rheumatism in Europe) one of the 8 standing committees of Eular, working together with Eular9s other pillars, the scientific community and health professionals, rank this as one of the most important topics and as high priority. Activities are organized for raising awareness, educating patient delegates and supporting National activities in this respect and it also acts as a platform to enhance and exchange knowledge, skills and best practice between our national organizations. Raising awareness is very much connected to the recognition of RMDs as major diseases and for the implementation of measures and in forwarding strategy plans for the early diagnosis and the effective management of RMDs, and also legislations for the full inclusion of people with RMDs in society and for more funds for research. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6308
THU0091 Aquaporin Expression in the Synovial Tissues of Patients with Osteoarthritis and Rheumatoid Arthritis
Authors: N. Tatematsu, Y. Waguri-Nagaya, M. Nagahara, K. Ikuta, M. Aoyama, K. Asai, T. Otsuka
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Aquaporins (AQPs) are usually present at the plasma membrane, where they regulate the influx and outflow of water and small molecules. They are important for the regulation of water homoeostasis in cells and organisms. An analysis of AQP molecular mechanisms in synovial tissues may suggest new treatments for hydrarthrosis. <h3>Objectives</h3> To determine whether AQPs are expressed in the synovial tissues of patients with OA and RA, and to examine the patterns of expression in patients with and without hydrarthrosis. <h3>Methods</h3> Synovial tissue samples were obtained from patients with OA and with RA. AQPs mRNA were detected in synovial tissue samples from patients with OA and RA using RT–PCR. Fibroblast-like synoviocytes (FLSs) from patients with OA and RA were cultured and stimulated with TNF-α. The expression of AQPs in FLSs was examined using RT–PCR and western blot analyses and the function of aquaglyceroporin was examined by a glycerol uptake assay. <h3>Results</h3> The presence of AQP1, AQP3, AQP7 and AQP9 mRNAs was confirmed in all of the synovial tissue samples from OA and RA patients. The expression levels of AQP9 were significantly higher in RA samples than in OA samples (P &lt; 0.01). AQP9 expression was significantly higher in synovial tissues from the OA patients with hydrarthrosis than in those without (P &lt; 0.05). AQP1 and AQP3 mRNA expression levels were not affected by TNF-α treatment. AQP9 mRNA and protein expression were strongly induced with TNF-α treatment in FLSs, whereas AQP1 and -3 mRNA expression levels were not affected by TNF-α treatment. [³H] glycerol uptake was significantly higher in OA FLSs treated with TNF-α. <h3>Conclusions</h3> This study showed that AQP1, AQP3 and AQP9 were expressed in synovia from OA and RA patients. The synovial tissues of patients with OA with hydrarthrosis significantly expressed more AQP9s than without hydrarthrosis. AQP9 expression was strongly induced in FLSs with TNF-α. AQP9 might be related to the pathogenesis of hydrarthrosis and inflammatory synovitis. The therapy focusing on AQP9-mediated water transport would be a new approach to hydrarthrosis. <h3>References</h3> Nozaki K, Ishii D, Ishibashi K. Intracellular aquaporins: clues for intracellular water transport? Pflugers Arch 2008; 456:701–7. Verkman AS. Aquaporin water channels and endothelial cell function. J Anat 2002;200:617–27. Magni F, Sarto C, Ticozzi D et al. Proteomic knowledge of human aquaporins. Proteomics 2006;6:5637–49. Tsukaguchi H, Weremowicz S, Morton CC et al. Functional and molecular characterization of the human neutral solute channel aquaporin-9. Am J Physiol Renal Physiol 1999;277:685–96. Nagahara M, Waguri-Nagaya Y, T Yamagami, Aoyama M, Tada T, Inoue K. Asai K, Otsuka T. TNF-a induced aquaporin 9 in synoviocytes from patients with OA and RA. Rheumatol 2010;49 :898-906. <h3>Disclosure of Interest</h3> None Declared
CLINICAL IMPACT OF APPROPRIATE USE CRITERIA (AUC) FOR CORONARY REVASCULARIZATION IN CONSECUTIVE, NON-SELECTED PATIENTS TREATED WITH DRUG-ELUTING STENTS: INSIGHTS FROM THE DESIRE REGISTRY
Authors: Jose de Ribamar Costa, Ana Cristina Seixas, Amanda Sousa, Adriana Moreira, Ricardo Costa, Lucas Damiani, Cantídio Campos Neto, Ricardo Pavanello, Galo Maldonado, Manuel Cano, J. Eduardo Sousa
Journal: Journal of the American College of Cardiology (2016)
SAT0295 Determining the Prevalance of Sacroiliitis in Behcet's Disease by Magnetic Resonance Imaging
Authors: V. Cobankara, M. Topaloglu, A. Balkarlı, N. Karabulut, N. Akkoyunlu, A. Karabulut
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Behcet9s disease (BD) is a multisystem inflammatory disease with oral and genital ulcers. It was classified as one of the seronegative arthritis in sixties and seventies due to occurrence of oral ulcers, arthritis, uveitis, and erythema nodosum like symptoms. The prevalence of sacroilitis was detected as 65% with conventional radiography in early reports. However in a controlled study, prevalence of sacroilitis was reported as 35% which was comparable with the healthy control group. Magnetic resonance imaging (MRI) is the most sensitive method for detection of sacroiliitis in patients with spondyloarthropathies. <h3>Objectives</h3> In this study we aim to determine the prevalence of sacroiliitis in patients with Behçet disease by using MRI and compare with the healthy control group. <h3>Methods</h3> Fifty patients (25 M, 25 FM) having Behçet9s disease according to international Behçet9s disease study group classification criteria were included into the study. Fifty healthy people (25 M, 25 FM) who did not have any musculoskeletal symptom were taken as control group. Medical history was taken and physical examination was performed for both study and control groups. Subjects in control group who had musculoskeletal symptoms were excluded from the study. Routine laboratory tests were obtained from the study group. Sacroiliac joint MRI exams were taken for both study and control groups and evaluated by two radiologists who were blinded to the subjects. <h3>Results</h3> Sacroiliitis were detected in seven (14%) patients with BD and in eight (16%) subjects in the control group. There was no statistically significant difference between two groups for the prevalence and presence of active and chronic findings of sacroiliitis (p&gt;0.05). No correlation was detected between acute phase reactants andsacroiliitis in patients with Behçet9s disease. <h3>Conclusions</h3> This is the first study which researches the prevalence of sacroiliitis by using MRI in patients with Behçet9s disease. Although Behçet9s disease has symptoms of spondyloarthropaties the prevelance of sacroiliitis which is most important clinical finding of spondyloarthropathy is not different from the healthy control group. <h3>Acknowledgements</h3> This study was supported by Pamukkale University Scientific Research Projects Coordination Unit <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4085
Abstract 1295: Inhibition of clonogenicity and xenograft tumor growth by activation and/or over-expression of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ).
Authors: Pei-Li Yao, Michael G. Borland, Prasad Krishnan, Bokai Zhu, Frank J. Gonzalez, Jeffrey M. Peters
Journal: Cancer Research (2013)

Abstract The peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) regulates a variety of biological processes but the function of PPARβ/δ in carcinogenesis remains controversial. Stable human cancer cell lines (A431, MDA-MB-231 and MCF7) that constitutively over-express PPARβ/δ were produced to effectively examine the role of this receptor in human cancer models. Ligand activation of PPARβ/δ both in MDA-MB-231 (ER-negative) and MCF7 (ER-positive) cells over-expressing PPARβ/δ cells caused significantly decreased clonogenicity compared to controls. Over-expression of PPARβ/δ reduced tumor volumes and tumor weights of ectopic xenografts from both MDA-MB-231 and MCF7cells compared to controls. Ligand activation of PPARβ/δ caused an even greater reduction of tumor volumes and tumor weights compared to controls. Interestingly, similar results were observed in the human epidermoid carcinoma cell line A431 and other human cancer cell lines. Ligand activation of PPARβ/δ strongly inhibited clonogenicity in A431 cells over-expressing PPARβ/δ. Xenografts from A431 control cells rapidly developed tumors while tumors were barely detectable in A431 cells over-expressing PPARβ/δ. These observations demonstrate the inhibitory effect of activating or over-expressing PPARβ/δ on tumorigenesis in human cancer cell lines. This suggests that PPARβ/δ suppression of tumorigenicity may be mediated through common mechanisms. Citation Format: Pei-Li Yao, Michael G. Borland, Prasad Krishnan, Bokai Zhu, Frank J. Gonzalez, Jeffrey M. Peters. Inhibition of clonogenicity and xenograft tumor growth by activation and/or over-expression of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ). [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1295. doi:10.1158/1538-7445.AM2013-1295
Recommendations on Prophylaxis and Therapy for Disseminated Mycobacterium avium Complex Disease in Patients Infected with the Human Immunodeficiency Virus
Authors: Henry Masur
Journal: New England Journal of Medicine (1993)

Special Report from The New England Journal of Medicine — Recommendations on Prophylaxis and Therapy for Disseminated Mycobacterium avium Complex Disease in Patients Infected with the Human Immunodeficiency Virus